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Abstract
Trypanosoma brucei gambiense infection is widely considered an anthroponosis, although it has also been found in
wild and domestic animals. Thus, fauna could act as reservoir, constraining the elimination of the parasite in hypo-
endemic foci. To better understand the possible maintenance of T. b. gambiense in local fauna and investigate the
molecular mechanisms underlying adaptation, we generated adapted cells lines (ACLs) by in vitro culture of the
parasites in different mammalian sera. Using specific antibodies against the Variant Surface Glycoproteins (VSGs)
we found that serum ACLs exhibited different VSG variants when maintained in pig, goat or human sera. Although
newly detected VSGs were independent of the sera used, the consistent appearance of different VSGs suggested
remodelling of the co-transcribed genes at the telomeric Expression Site (VSG-ES). Thus, Expression Site
Associated Genes (ESAGs) sequences were analysed to investigate possible polymorphism selection. ESAGs 6 and
7 genotypes, encoding the transferrin receptor (TfR), expressed in different ACLs were characterised. In addition, we
quantified the ESAG6/7 mRNA levels and analysed transferrin (Tf) uptake. Interestingly, the best growth occurred in
pig and human serum ACLs, which consistently exhibited a predominant ESAG7 genotype and higher Tf uptake than
those obtained in calf and goat sera. We also detected an apparent selection of specific ESAG3 genotypes in the pig
and human serum ACLs, suggesting that other ESAGs could be involved in the host adaptation processes.
Altogether, these results suggest a model whereby VSG-ES remodelling allows the parasite to express a specific set
of ESAGs to provide selective advantages in different hosts. Finally, pig serum ACLs display phenotypic adaptation
parameters closely related to human serum ACLs but distinct to parasites grown in calf and goat sera. These results
suggest a better suitability of swine to maintain T. b. gambiense infection supporting previous epidemiological results.
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Introduction
Human African Trypanosomiasis (HAT) is caused by two
subspecies of the hemoflagellate Trypanosoma brucei: T. b.
gambiense and T. b. rhodesiense, both transmitted by the
tsetse fly (Diptera; Glossinidae; Glossina sp.), their only known
vector. Despite their high biological and genetic similarity, T. b.
gambiense and T. b. rhodesiense present phenotypic
differences observed at clinical and epidemiological levels
[1–3]. T. b. rhodesiense is considered a zoonosis and triggers
in humans an acute and severe disease which leads to fatality
in weeks or months if untreated. T. b. gambiense is considered
an anthroponosis, causing a chronic wasting disease and is
responsible for most of HAT cases [4–6]. Assuming that the T.
b. gambiense reservoir is mainly human, control programs and
elimination initiatives have been focused on the early detection
of the parasite in this host [7–11]. However, this parasite has
also been detected in a wide range of domestic and wild
mammalian species and several authors consider these
infections relevant for the maintenance of the parasite in the
epidemiological cycle under hypo-endemic conditions, where
no human cases have been detected for a long time [12–15].
To investigate the role played by local fauna as reservoir of
T. b. gambiense, several direct or indirect approaches have
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been implemented. In the past, some authors attempted to
compare, using molecular markers, genotypes circulating
between humans and animals harbouring T. b. gambiense.
Despite epidemiological evidence for the parasite in others
mammals, the possibility of transmission from animals to
human and the implication of these alternative hosts in the
epidemiological cycle of the disease are still controversial
[16,17].
Host ability to allow the parasite survival for long periods is a
requirement to define new reservoirs. Thus, in vivo follow up of
infected animals can be performed to evaluate T. b. gambiense
maintenance in different candidate species [18]. This type of
studies has been hampered due to certain associated
limitations, such as risk of environmental contamination, low
sensitivity of available tests to detect the parasite, parasitaemia
fluctuation due to the host immune response, difficult isolation
of the parasite to perform further analyses and absence of
human controls due to obvious ethical reasons.
To better control the growth conditions of the parasite and
perform cellular and molecular analyses, in vitro approaches
are preferred. Such approaches have already been applied to
study T. b. brucei adaptation to different mammalian sera
[19,20]. These studies focused on Expression Site Associated
Genes (ESAGs) since they are good candidates for being
involved in adaptation because of the large repertoire of
families and different alleles. In addition, they are
polycistronically transcribed in the telomeric Expression Site
(ES) along with the gene that codifies the protein involved in
antigenic variation: Variant Surface Glycoprotein (VSG) [21,22].
T. b. brucei has about 15 VSG-ESs although only one is
transcribed at a given time while the others remain repressed,
providing the expression of a particular combination of ESAGs
in a mutually exclusive manner [23]. The transcriptional
activation/inactivation of genes in the VSG-ESs is a highly
regulated mechanism [24–27], potentially allowing the parasite
to quickly respond to any environment change.
Several studies showed that the genes coding for the
transferrin receptor (TfR) were the two ESAGs closest to the
promoter region, ESAG6 and 7 [28–30]. In T. b. brucei, the
different copies of ESAG6/7 sequences are highly polymorphic
in regions corresponding to transferrin (Tf) binding sites
[31,32]. A controversial hypothesis, still under debate,
proposed that the genetic variability of this receptor would
provide the parasite with a range of affinities for Tf from
different mammalian hosts, which may differ by 30% in amino
acid sequence [19,33–35]. Comparable studies have never
been conducted for T. b. gambiense and little is known about
ESAG sequences and the telomeric VSGs that are expressed,
since complete VSG-ESs sequences of this parasite are not
available [36].
Field epidemiological data suggest that a peri-domestic T. b.
gambiense life cycle, involving mammals such as pigs and
goats, might occur in West Africa [12,15,37]. We generated
serum-adapted cell lines (ACLs) and analysed associated
features to investigate the ability of this parasite to grow in
different mammalian sera. Initial analysis showed a correlation
between adaptation to different sera and expression of new
VSGs, suggesting VSG-ES remodelling. Further analyses of
ESAG6, ESAG7 and ESAG3 genotypes, TfR gene expression
and Tf uptake were conducted to investigate the molecular
mechanisms underlying adaptation responses in T. b.
gambiense.
Results and Discussion
T. b. gambiense adapts to grow in different mammalian
sera
Our first evaluation of the adaptation process was to
measure the growth rate of cell lines maintained in different
sera. Three goat serum (GS1, GS2 and GS3), three pig serum
(PS1, PS2 and PS3) and four human serum (HS1, HS2, HS3
and HS4) independent adaptation experiments were
performed. Duplication time of the ACLs, after twenty-five
passages in the corresponding serum, was compared to the
same line before adapting, i.e. at the initial two passages
(Figure 1). Human and pig serum ACLs exhibited a significant
increase in the rate of proliferation, with a faster duplication
time (from 13.2 ± 2.28 to 8.94 ± 0.49 hours in human serum
and from 16.17 ± 1.9 to 9.59 ± 0.53 hours in pig serum,
p<0.01), suggesting an efficient adaptation. However, goat
serum ACLs showed a minor increase in proliferation rate with
a smaller reduction in the duplication time (from 14.57 ± 2.63 to
11.1 ± 1.14 hours, p<0.05). Pig serum ACLs exhibited the
faster proliferation rate after the adaptation (40.6% lower than
pre-adapted line) whereas goat serum ACLs showed a lower
reduction in the duplication time (23.8%). The original line,
maintained in foetal calf serum (FCS), presented a duplication
time of 13.5 ± 1.78 hours.
An effective reservoir should be able to harbour the
pathogen for long-term periods while the parasite retains the
capacity to infect other hosts. It is widely assumed that T. b.
gambiense has a constitutive resistance to normal human
serum (NHS), contrary to T. b. rhodesiense, which acquires
resistance to NHS only when the SRA (Serum Resistance
Associated) gene, a particular ESAG, is expressed from the
active VSG-ES [38–42]. Once adapted, our cell lines were
cloned and tested against NHS to address whether, even after
a long-term passage in other mammal sera, T. b. gambiense
ACLs was still resistant to human serum. All the clones
analysed (27 from calf, 17 from pig and 46 from goat sera)
were fully resistant to NHS, while sensitive T. b. brucei controls
systematically were lysed within 16 hours, confirming the
constitutive nature of the NHS resistance in T. b. gambiense.
This feature would potentially enable this parasite to infect
humans after being maintained in animal cycles.
A previous study on the maintenance of T. b. gambiense in
experimentally infected pigs under controlled conditions
showed that T. b. gambiense causes an asymptomatic
infection in this species evolving towards spontaneous cure in
3-4 months [18]. However, we developed an in vitro culture
system that allows the parasites to adapt to different animal
sera, which permitted us to carry out molecular analyses of
these ACLs under controlled conditions. In addition, our in vitro
approach overcomes selection due to the host immune
response, physiological changes or individual animal variability,
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allowing us to analyse molecular aspects associated only with
the adaptation process.
Adaptation to mammalian sera results in selection of
new VSGs
Previous work in T. b. brucei suggested that the parasite’s
ability to adapt to various mammalian hosts is linked to the
differential expression of polymorphic genes of the VSG-ESs, a
polycistronically transcribed locus with high genetic plasticity
[22,43]. To investigate the role of VSG-ESs in the adaptation of
T. b. gambiense to different hosts, we first analysed the
expressed VSG in the different ACLs, as a marker of possible
VSG-ES changes. The VSG is a highly abundant protein
allowing the direct visualization in total protein extracts of the
ACLs. Figure 2B shows an abundant band that varies in size
among different lines, suggesting that the VSGs expressed in
the ACLs were distinct from those expressed in the original
line, maintained in FCS. The high intensity band at 70 kDa
observed in the HS1 line was identified by peptide mass
fingerprinting as contaminant human albumin.
To characterize these prominent bands, we generated
antibodies against the VSGs expressed in the original cell line
(LiTat 2.1) and HS1 line (LiTat 3.1) (see Material and
Methods). Western Blot (WB) analysis using a mouse
monoclonal antibody (mAb) against the original VSG
suggested specificity since it exclusively recognizes the VSG
present in the FCS ACL (Figure 2C). Likewise, the rabbit
antiserum developed against the amino terminal fragment of
the LiTat 3.1 only recognized the VSG expressed in the HS1.
Although we did not isolate and characterize other expressed
VSGs in pig and goat serum ACLs, the different sizes observed
by protein staining and the lack of detection by WB using anti-
LiTat 2.1 and anti-LiTat 3.1 antibodies suggested that these
protein bands correspond to different VSGs. Thus, we detected
at least five distinct VSGs during the adaptation assays.
Immunofluorescence (IF) experiments were also performed
with the specific mAb anti-LiTat 2.1 (Figure 3). This analysis
revealed that nine out of ten ACLs expressed a different
dominant VSG. Parasites selected in pig and goat sera yielded
a population where at least 93.5% of cells expressed a VSG
distinct from the original one. Three out of the four human
serum ACLs (lines HS1, HS2 and HS4), also expressed
different VSGs (100%, 96.5% and 87.4% of VSG change
respectively), and only a single human serum ACL (HS3)
maintained the original LiTat 2.1.
IF analysis using anti-LiTat 3.1 showed that six out of the ten
new ACLs expressed on their surface LiTat 3.1 as the more
frequently VSG: three of human ACLs (99.8%, 93% and
85.6%), two of goat (79.5% and 92.2%) and one of pig
(91.5%). The two remaining pig ACLs expressed neither LiTat
2.1 nor LiTat 3.1, while only 30% of the GS3 expressed LiTat
3.1 (Figure 3B).
A non-clonal population was used for these studies since it
offers a more suitable initial diversity for selection, as reported
previously in T. b. gambiense [44]. In spite of this, IF analysis
showed the stable expression of the LiTat 2.1 VSG in the
original line after culture with FCS for several months. LiTat 3.1
was the most common VSG variant detected, probably due to
its presence in the original population and further VSG-ES
selection.
These results suggest that the type of VSG expressed is
independent of the serum used for selection. However, in all
cases but one (HS3), we detected a switch in the VSG
expressed in the ACLs suggesting that VSG-ES changes in the
co-expressed ESAGs might be involved in the adaptation
process.
Figure 1.  Duplication time of ACLs after adaptation.  Histogram showing the duplication time of T. b. gambiense (ELIANE strain)
before and after 25 passages (75-105 days) in HMI9 supplemented with 20% of different mammalian sera. Mean ± SD of at least
three independent experiments is shown. Student´s t-test showed significant differences in human and pig serum ACLs between
before and after adaptation (* p<0.05; ** p<0.01). FCS: Foetal Calf Serum, ACL: adapted cell line.
doi: 10.1371/journal.pone.0085072.g001
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ESAG7 shows a specific genotype in pig and human
ACLs
Differential VSG expression after growth selection using
different animal sera has been previously reported in T. b.
brucei [33,34]. In particular, expression of polymorphic ESAGs
has been proposed to explain the adaptation mechanism to
mammalian sera. Although this hypothesis is still not
definitively proved, expression of distinct ESAGs 6 and 7,
encoding the polymorphic TfR [30], may have significant effects
on the binding affinity for diverse mammalian Tfs [19,34].
In order to investigate whether adaptation in the ACLs
generated in this study could be associated with specific TfR
selection, we first characterized the cDNA sequence diversity
of ESAGs 6 and 7 in all our ACLs (Figure 4 and Table 1). We
utilized a single set of primers to amplify both genes and after
sequencing the PCR fragments we were able to distinguish
each gene and their genotypes.
Summary of ESAG6/7 genotypes distribution amongst ACLs.
Data represent the number of times a given genotype was
obtained during genotyping analysis. Significant association
between serum and genotype, assessed by Likelihood Ratio
Test completed with residues analysis, is marked with an
asterisk (*). For analysis, lines were grouped by serum species.
Partial ORF was used for DNA genotyping (673-676 bp). Only
TfR region was used in alignments at protein level. FCS: foetal
calf serum, GS1/2/3: goat serum (adaptation experiments 1, 2
or 3), HS1/2/3/4: human serum (adaptation experiments 1, 2, 3
or 4), PS1/2/3: pig serum (adaptation experiments 1, 2 or 3).
Overall, we obtained five ESAG7 and four ESAG6
genotypes, defined as single nucleotide changes in the
sequence. Table 1 and Figure 4 show the genotype frequency
obtained for each ACL and Figure S1A shows a clustering tree
for both genes. Average DNA diversity was 4.56% (ranging
from 1.65% to 6.07%) and 3.88% (from 0.15% to 7.58%) for
ESAG7 and ESAG6 respectively (in terms of number of
nucleotide substitutions per polymorphic site). Interestingly,
protein alignments of the Tf binding regions yielded only two
types of ESAG6 out of four genotypes (one represented only
by a single clone), while four ESAG7 proteins corresponding to
five different genotypes were detected (Figure 5A and Table 1).
Low diversity of T. b. gambiense ESAG6 has been reported
previously [36]. The main genotypes found in our study,
Tbg6_4 and Tbg6_3, correspond to type 10 and 7 respectively,
described by Young et al. [36]. Tbg6_1 shares 99% homology
(675/676 nucleotides) with type 8 and Tbg6_2 is highly similar
to types 7 and 5 (99% homology, 674/676 in both cases). The
authors suggested that T. b. gambiense shows less ESAG6
diversity because is highly adapted to the human host. Our
data also showed less variability in ESAG6 genotypes
suggesting that most T. b. gambiense VSG-ESs contain
ESAG6 copies encoding high-affinity TfR for human Tf.
Figure 2.  VSG expression in ACLs..  (A) Schematic representation of a canonical VSG-Expression Site and the two main
mechanisms of antigenic variation in T. brucei. Black arrows indicate the promoter sequence and blue arrows the active start
transcription site. The thick black line mirrors the transcribed genes. The striped boxes are the 70-base-pair repeats upstream the
VSG gene and white triangles represent telomeric repeats. Coloured boxes denote ESAG and VSG genes. Active VSG-ES can be
silenced and another telomeric VSG-ES becomes active by in situ switch (above). Alternatively recombination events in any part (or
parts) of the active VSG-ES can occur by homologous recombination, inserting new gene/s from another VSG-ES or non-telomeric
locations. (B) Ponceau staining of total protein extract from ACLs showing different VSGs (marked with an arrow). Equivalent
amount of 5 x106 parasites was loaded per well. Molecular weight is expressed in kDa. (C) WB analysis of VSGs expressed by
different ACLs using anti-LiTat 2.1, anti-LiTat 3.1 and anti-221 antibodies [25]. Anti-Tubulin was used as loading control. Equivalent
amount of 1 x 105 parasites was loaded per well. ACL: adapted cell line. FCS: foetal calf serum, GS1/2/3: goat serum (adaptation
experiments 1, 2 or 3), HS1/2/3/4: human serum (adaptation experiments 1, 2, 3 or 4), PS1/2/3: pig serum (adaptation experiments
1, 2 or 3), WB: Western Blot.
doi: 10.1371/journal.pone.0085072.g002
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Contrary to ESAG6, we detected an interesting correlation
between the serum used for selection and the ESAG7 type.
Genotype Tbg7_5 correlated to pig serum, whereas Tbg7_1
was significantly associated with human serum (p< 0.01).
Conversely, adaptation in goat serum yielded a more diverse
pattern (all four ESAG6 and five ESAG7 genotypes were found
in goat serum ACLs). Van Luenen et al. [34] investigated in
detail changes in T. b. brucei ESAG6/7 expression upon
adaptation to growth in dog serum. Their data showed that the
parasite might respond to changes in serum either by in situ
switching to another VSG-ES to express a new ESAG6/7 with
higher affinity for dog Tf, or by upregulation of ESAG7
expression from an inactive VSG-ES promoter-proximal region,
resulting in expression of different ESAG7 genotypes. A similar
upregulation of ESAG6/7 from an inactive VSG-ES was
described after deletion of these genes from the active VGS-
ES [45]. We also detected a major ESAG7 mRNA type in some
ACLs and others less abundant, suggesting a residual
Figure 3.  Antigenic variation in ACLs.  (A) Immunofluorescence analysis of different T. b. gambiense ACLs. Monoclonal
antibodies anti-LiTat 2.1 VSG and rabbit antiserum anti-LiTat 3.1 VSG were used. White bar represents the scale, set at 5 µm. (B)
Frequency of expressed VSG (LiTat 2.1, LiTat 3.1 or other) in ACLs from goat, pig, human and calf sera. Cells were manually
counted by IF (n≈500 per sample). FCS: foetal calf serum, GS1/2/3: goat serum (adaptation experiments 1, 2 or 3), HS1/2/3/4:
human serum (adaptation experiments 1, 2, 3 or 4), PS1/2/3: pig serum (adaptation experiments 1, 2 or 3).
doi: 10.1371/journal.pone.0085072.g003
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Figure 4.  ESAG diversity in ACLs.  Graphic representation of ESAG genotype diversity. Each ring is divided in 2-4 inner circles
representing each independent experiment. Unless otherwise is indicated, ACLs distribution in each ring is as indicated in ESAG7
row. Each genotype is represented in a different colour according to indicated in the graph. Partial ORF was used for DNA
genotyping (673-676 bp in ESAG6/7 and 853 bp in ESAG3). FCS: foetal calf serum, GS1/2/3: goat serum (adaptation experiments
1, 2 or 3), HS1/2/3/4: human serum (adaptation experiments 1, 2, 3 or 4), PS1/2/3: pig serum (adaptation experiments 1, 2 or 3).
doi: 10.1371/journal.pone.0085072.g004
Table 1. ESAG6/7 genotype diversity.
Genotype FCS GS1 GS2 GS3 HS1 HS2 HS3 HS4 PS1 PS2 PS3 Total
Tbg7_1 7 1 5 5 10* 7* 11* 11*   1 58
Tbg7_2  1          1
Tbg7_3  6*          6
Tbg7_4  1          1
Tbg7_5  3 1 3  1  1 2* 4* 14* 29
Tbg6_1    1        1
Tbg6_2   1  1     1  3
Tbg6_3 2  1 3 1  2     9
Tbg6_4 2  3 2  3 2 1 10 10  33
Protein TfR             
Tbg7_1/2 7 2 5 5 10 7 11 11   1 59
Tbg7_3  6          6
Tbg7_4  1          1
Tbg7_5  3 1 3  1  1 2 4 14 29
Tbg6_1    1        1
Tbg6_2/3/4 4  5 5 2 3 4 1 10 11  45
Total 11 12 11 14 12 11 15 13 12 15 15 141
doi: 10.1371/journal.pone.0085072.t001
Trypanosoma brucei gambiense and Adaptation
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e85072
expression from inactive VSG-ESs. In order to investigate
whether the different ESAG7 mRNA sequences from ACLs
were due to low expression of inactive VGS-ESs or to
population variability [46], we cloned and sequenced the
expressed ESAG6/7 of two clones obtained from the human
serum ACL HS2 and two from HS3. While most of the clones
expressed a single ESAG6/7 genotype, in the clone 2 from
HS3, we found two different ESAG7s genotypes, one more
abundant corresponding to that detected in the HS3 (data not
shown). These data suggest that polymorphisms in ESAG7
should not be entirely attributed to mixed population expressing
different VSG-ESs, but rather to the expression from inactive
VSG-ESs.
It has been reported that after T. b. brucei adaptation to
canine serum, ESAG7 genotypes distinct to the original wild
type line were frequently obtained, whereas the ESAG6 type
usually remained constant [34]. These data are consistent with
our results, suggesting that ESAG7 diversity, rather than
ESAG6, is relevant for the adaptation to different Tfs.
In summary, specific genotypes of ESAG7 were identified in
human and pig serum ACLs. The selection of these genotypes
may confer phenotypic advantages during the adaptation
process and be directly related to the increased competency in
growth compared to goat and calf serum ACLs (Figure 1).
Pig ACLs show higher human transferrin uptake
To gain insight on the role of differential ESAG6/7 expression
in the adaptation process, we analysed Tf uptake in all our
ACLs. We performed the experiments with human holo-Tf (iron
saturated) since humans are considered the main T. b.
gambiense host. Sub-physiological concentration of Tf was
used in order to better track the uptake variations (20 μg/ml, i.e.
around 50 fold less holo-Tf relative to normal serum and 10 fold
less relative to our culture conditions). Maximum uptake was
reached between 5 to10 minutes of incubation in all ACLs
(Figure 6A). Human and pig serum ACLs showed the most
efficient uptake with 16.25 ± 1.00 and 16.52 ± 2.45 FAU
(fluorescence arbitrary units) at 5 minutes of incubation,
respectively. Significant differences were detected in Tf uptake
when all ACLs were compared. Pair wise post-hoc analyses
showed that goat serum ACLs did not significantly differ from
the original line at any incubation time, whereas pig and human
serum ACLs uptake increased by 60% respective to the other
lines (p= 0.017 and p= 0.013 at 5 minutes of incubation time,
respectively). However, the Tf uptake differences could be due
not only to receptor mediated endocytosis variation but also to
changes in the endocytic rate. Thus, we carried out fluid-phase
endocytosis assays using Alexa Fluor® 488-labelled dextran
10,000 (Molecular Probes) [47] to normalize the transferrin
uptake (Figure 6B). After normalization, pig serum ACLs
conserved a higher uptake of Tf compared to goat and calf
serum ACLs, indicating that at least 36% of uptake increase
was not due to differences in the endocytosis rate. Thus, higher
Tf uptake in pig serum ACLs could be attributed, at least in
part, to the specific ESAG7 genotype (Tbg7_5) expressed in
these lines. Normalized Tf uptake values of human serum
ACLs, contrary to pig serum ACLs, suggest that a higher
endocytic rate is influencing the Tf uptake data. This can
explain why calf and human serum ACLs have different Tf
uptake while sharing similar ESAG6/7 genotypes. In addition,
increased ESAG6/7 mRNA levels were consistently detected in
human serum ACLs (ranged between 4.95 ± 0.34 to 7.81 ±
1.13 fold relative to original line, Figure 6C), suggesting higher
protein levels in the flagellar pocket. Although we have not
properly tested this hypothesis by protein detection, the
modulated expression of TfR at both mRNA and protein levels
have been well described during adaptation, showing that
ESAG6/7 transcript levels largely mirror the protein TfR amount
Figure 5.  Alignment of Tf binding sites (ESAG6/7) and polymorphic ESAG3 regions.  Amino acid alignment of polymorphic
regions of ESAG6/7 (A) and ESAG3 (B). Tf binding sites are highlighted with red squares. Other polymorphic regions of ESAG6/7
are marked with black boxes. Polymorphic regions of ESAG3 are shown. I: S103-E119; II: L171-K189; III: A/G215-D/E244; IV:
A309-R/E321. T. b. brucei ESAGs 6, 7 and 3 are shown in red.
doi: 10.1371/journal.pone.0085072.g005
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in the flagellar pocket [20,34]. We do not have a satisfactory
explanation of why the endocytic rate increases upon culture in
presence of human serum, although it is possible that several
unknown factors present in human blood, the T. b. gambiense
main reservoir, could provide benefits to the parasite in
essential processes such as the endocytic pathway.
GS1 and GS3 showed even higher expression of ESAG7
mRNA levels than human serum ACLs (20.16 ± 0.31 and 13.4
± 0.99 fold relative to FCS ACL), although this did not entail a
higher Tf uptake. As we did not observe a more efficient
adaptation phenotype, we could not attribute this finding to a
clone selection as may occur in human serum ACLs. Rather,
we hypothesize that continuous culture with goat serum
resulted in upregulation of mRNA levels of ESAG6/7 as
previously described in T. b. brucei using dog serum [20],
leading to a diverse expression pattern (Figure 4).
Although efficient uptake of Tf by the TfR is essential for
parasite growth [48], some authors would not consider it as a
selection factor under in vivo conditions, since even a low
affinity receptor could provide the parasites with the low iron
requirement they need [49]. Chronic T. b. gambiense infections
last months or even years and the immune response of the
host produces a wide range of antibodies against parasite
antigens such as TfR [50]. It is known that these anti-TfR
antibodies can compete with Tf for binding to TfR [19,51] and
Tf uptake inhibition by these means seems especially
substantial when a low affinity TfR is expressed [19].
Additionally, indirect evidences suggest that Tf availability in
the flagellar pocket, where TfR is expressed, could be up to 30
fold lower compared to its concentration in surrounding
medium [20]. Altogether, these data suggest that a high affinity
TfR could be important for the parasite to ensure sufficient Tf
uptake in vivo. As proposed by van Luenen et al. [34] this issue
will need further analysis with trypanosomes isolated from wild
fauna to elucidate whether there is a differential TfR selection
upon parasite adaptation in different mammals. This would be
especially difficult in T. b. gambiense, given the low prevalence
reported in the local fauna [12].
Figure 6.  Tf uptake and mRNA ESAG6/7 expression levels.  (A) Tf uptake of different ACLs. Mean ± SD of three (goat and pig)
or four (human) sera independent adaptation experiments and three independent measures of calf serum ACL are shown. Uptake is
expressed in FAU (fluorescence arbitrary units). One-way ANOVA test was performed (* p< 0.05; ** p<0.01). (B) Normalized Tf
uptake of different ACLs. Data from Figure 6A were normalized with dextran uptake at 10 minutes of incubation (data not shown).
One-way ANOVA test was performed (* p< 0.05; ** p<0.01). Human holo-Tf (iron saturated) was used at final concentration of 20
μg/ml. (C) Histogram showing relative expression of mRNA measured by qRT-PCR of ESAG6, ESAG7 and TbHpHbR in all ACLs.
Mean ± SD of two different measures is shown. Expression values are plotted in relative expression units, calculated relative to
ATM (PI3Kinase-like -Tbb927.2.2260-) expression. Myosin housekeeping gene is also shown [25]. ACL: adapted cell line,
TbHpHbR: Haptoglobin-Hemoglobin receptor, FCS: foetal calf serum, GS1/2/3: goat serum (adaptation experiments 1, 2 or 3),
HS1/2/3/4: human serum (adaptation experiments 1, 2, 3 or 4), PS1/2/3: pig serum (adaptation experiments 1, 2 or 3).
doi: 10.1371/journal.pone.0085072.g006
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Recently, the mechanism of T. b. gambiense resistance to
human serum has been discovered [52]. This is consequence
of multiple factors as the expression of TgsGP gene and the
reduction/inactivation of another receptor located in the
flagellar pocket: the haptoglobin-hemoglobin receptor
(TbHpHbR), involved in trypanolytic factor 1 (TLF-1)
internalization [52]. Since no previous molecular studies on T.
b. gambiense adaptation in different mammals are available,
we decided to study these factors in our serum ACLs.
TgsGP gene is traditionally used as marker of T. b.
gambiense group 1 [53,54]. This gene was detected by PCR
from genomic DNA before and after the adaptation process in
all our ACLs (data not shown). On the other hand, we
measured the transcripts level of TbHpHbR, whose expression
is known to be downregulated in T. b. gambiense [55]. As this
receptor also binds haptoglobin-hemoglobin complexes of the
host in order to incorporate heme [56], one could expect that
upon non-human mammalian serum adaptation (i.e. in absence
of human TLF-1), TbHpHbR levels could vary. Our data,
however, demonstrate that the low TbHpHbR mRNA levels
represent a constitutive feature of T. b. gambiense and,
contrary to ESAG6/7 transcripts, remain stable upon adaptation
(Figure 6C). This suggests that regardless of the serum used,
the amount of heme does not constitute a limiting factor for
parasite growth.
ESAG3 specific genotypes are selected in pig and
human ACLs
Concomitant to changes in the expression of different
ESAG7 genotypes, the expression of other ESAGs may also
change, since they are linked to the VSG-ES locus. Thus, we
decided to investigate possible variations in the expression of
ESAG3 in the ACLs, located further downstream of the VSG-
ES promoter. Although ESAG3 function is unknown, the
predicted protein contains a signal peptide in the N-terminal
that putatively targets the protein to the cellular surface,
suggesting an interaction with the host environment [22]. In
addition, ESAG3 is present in almost all VSG-ESs of T. b.
brucei [57].
Sequence analysis identified thirteen different genotypes
(see Figures 4, 5B, S1B and Table 2). Average DNA diversity
was 3.7% (ranging from 0.12% to 6.24%), in four polymorphic
regions (Figure 5B). Similar to ESAG6/7, we detected a more
abundant ESAG3 type in human and pig serum ACLs,
suggesting mono-allelic expression from a single active VSG-
ES. We observed significant correlation (p< 0.01) between
Tbg3_13 and Tbg3_1 genotypes in the pig serum ACLs and
Tbg3_9 in human serum ACLs (Table 2). However, HS4 had
no predominant genotype and expressed at least four different
ESAG3 types. Calf and goat serum ACLs also showed a
diverse expression pattern as occurred in ESAG6/7 genes
(Table S1). The lack of correlation between the expressed VSG
and the serum ACLs hinders the interpretation of the ESAG3
selection in human and pig serum ACLs. Although some
ESAG3 non-telomeric copies can exist as pseudogenes in
subtelomeric arrays both in T. b. gambiense [58] and T. b.
brucei [59], the transcription from VSG-ESs by RNA
polymerase I is much more efficient than a possible
transcription of genes mediated by RNA polymerase II from
chromosomal internal positions [22,60]. Therefore, genotypes
from active VSG-ESs are likely the most abundant type in the
cDNA utilized as template in our genotyping analysis. For
example, Tbg3_9, the most common type found in our study,
corresponds to an ESAG3 copy from an expression site
(TbgBES11) previously obtained during T. b. gambiense
genome sequencing (GenBank AEX08459.1) [58]. Tbg3_1,
another major genotype, and Tbg3_13, expressed mainly by
PS3, share 98% and 97% similarity, respectively, with ESAG3
from TbgBES17 (GenBank AEX08464.1). On the other hand,
residual expression of ESAG3 from inactive expression sites is
unlikely, since the gene is located far away from the promoter.
Thus, the expression pattern of ESAG3 in human and pig
serum ACLs together with the similarity with previously
reported data suggest that sequences obtained in these ACLs
derived from the active VSG-ES.
Summary of ESAG3 genotypes distribution amongst ACLs.
Data represent the number of times a given genotype was
obtained during genotyping analysis. Significant association
between serum and genotype, assessed by Likelihood Ratio
Test completed with residues analysis, is marked with an
asterisk (*). For analysis, lines were grouped by serum species.
Partial ORF was used for DNA genotyping (853 bp). FCS:
foetal calf serum, GS1/2/3: goat serum (adaptation
experiments 1, 2 or 3), HS1/2/3/4: human serum (adaptation
experiments 1, 2, 3 or 4), PS1/2/3: pig serum (adaptation
experiments 1, 2 or 3).
The apparent ESAG3 genotypic selection in human and pig
serum ACLs, together with the lack of VSG-serum correlation
could be explained by VSG-ES remodelling. In human and pig
serum ACLs, the selected genotypes (Tbg3_1, Tbg3_9 and
Tbg_13) might be a result of insertions of copies from either
non-telomeric sites or other VSG-ESs by gene conversion
driven by the high sequence homology (Figure S2) [57,61].
Recombination between VSG-ESs during a selection
procedure has been described in T. b. brucei during in vitro
selection using dog serum [34] and after adaptation to human
HDL [62]. It is possible that some active VSG-ESs observed in
this study, including that expressed in the original line
containing LiTat 2.1 VSG, lack full-length copies of ESAG3,
allowing the detection of genotypes from non-telomeric sites
and leading the diverse patterns found in other ACLs such as
calf and goat serum ACLs and HS4. Likewise, in T. b. brucei
five telomeric VSG-ESs with no functional copy of ESAG3 have
been described [57], including BES13/TAR56, which contains a
promoter region highly similar to that of the T. b. gambiense
VSG-ESs [36].
The predicted protein encoded by genotype Tbg3_1
associated with PS1 and PS2, was a truncated version due to
the presence of a stop codon insertion at the amino acid
position 232. This is not consistent with a selection process of
this gene and the selection of some particular ESAG3
genotypes could be a side effect of the selection of other
ESAGs present in the active VSG-ES. Alternatively, as PS1
and PS2 shared ESAG6, 7 and 3 genotypes, but different
VSGs, it is possible than the same active VSG-ES is being
transcribed in both ACLs (Table S1 and Figure S2). In this
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case, a recombination event could have occurred downstream
the ESAG3. The lack of apparent selection in some ACLs and
the truncated product encoded by PS1 and PS2 difficult the
interpretation of the role of ESAG3 in adaptation. However, we
cannot rule out that it may confer an advantage in the
adaptation. ESAG3 is a 368 amino acid protein, with an amino
terminal signal peptide, which lacks obvious transmembrane or
anchoring domains. It has been hypothesized that ESAG3 is
released into surrounding medium under undetermined
conditions [22]. Secreted proteins have been described as
important to parasite-host crosstalk in other organisms such as
Plasmodium berghei, Fusarium oxysporum, Sclerotinia
sclerotiorum, Toxoplasma gondii or Bacillus anthracis [63–66].
In summary, ESAG3 genotyping suggests two ACLs
clusters. The first group (calf and goat serum ACLs) displayed
high level of polymorphism, while the second group (pig and
human serum ACLs) showed more homogenous genotypes.
The former ones probably mirror the expression of non-
telomeric copies due to the lack of a functional ESAG3 gene in
the active VSG-ES. The latter ones appear to select a
particular genotype, suggesting expression from the active
VSG-ES.
Conclusions
T. b. gambiense was able to efficiently proliferate in vitro in
all mammalian sera tested. However, appearance of different
VSG variants has been consistently observed in this parasite
after adaptation, independently of the serum used. This
suggests that while changes in the VSG type are not
associated to sera selection, expression remodelling of the
VSG-ES ESAGs is probably required. ESAG polymorphism
analysis showed a lower degree of variations in pig and human
sera than in goat and calf serum ACLs, which is consistent with
the more efficient growth in pig and human sera, suggesting
swine as a more suitable reservoir than any other animal.
After adaptation to pig and human sera, these ACLs
exhibited an increase in human Tf uptake. In the case of pig
serum ACLs, high Tf uptake is associated with the expression
of a specific ESAG7 genotype while human serum ACLs
showed increased endocytic rate and probably TfR amount
based on mRNA levels. However, goat serum ACLs showed a
slower growth rate after adaptation, a larger ESAG6/7
genotype diversity and increased levels of ESAG6/7
transcripts, but still lower Tf uptake than human and pig serum
ACLs. These data suggest a quick modulated adaptation
response, as occurs in T. b. brucei, immediately after being
Table 2. ESAG3 genotype diversity.
Genotype FCS GS1 GS2 GS3 HS1 HS2 HS3 HS4 PS1 PS2 PS3 Total
Tbg3_1   2      11* 13*  26
Tbg3_2 1 2* 2*     1    6
Tbg3_3 1           1
Tbg3_4  1          1
Tbg3_5 1      1     2
Tbg3_6   1 1    2    4
Tbg3_7     1       1
Tbg3_8     1       1
Tbg3_9 2 1 3  6* 5* 10* 2*    29
Tbg3 _10    1        1
Tbg3_11 1           1
Tbg3_12 1           1
Tbg3_13 2 2  2    3  1* 15* 25
Protein             
Tbg3_1   2      11 13  26
Tbg3_2 1 2 2     1    6
Tbg3_3 1           1
Tbg3_4  1          1
Tbg3_5 1      1     2
Tbg3_6   1 1    2    4
Tbg3_7     1       1
Tbg3_8     1       1
Tbg3_9 2 1 3  6 5 10 2    29
Tbg3_10    1        1
Tbg3_11 1           1
Tbg3_12 1           1
Tbg3_13 2 2  2    3  1 15 25
Total 9 6 8 4 8 5 11 8 11 14 15 99
doi: 10.1371/journal.pone.0085072.t002
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exposed to dog serum [34]. Parasites seem unable to attain a
complete and stable adaptation in goat serum, since they still
show the short-term quick responses after at least seventy-five
days of culture.
ESAG3 genotypes also seemed to correlate with the serum
utilized in the adaptation, showing specific types expressed
mainly in human and pig serum ACLs, whereas in goat serum
ACLs a diverse pattern was noticed. As we discussed above,
although this selection is probably a side effect of the
rearrangement of VSG-ES to select other ESAG/s, these data
still suggest that the pressure upon sera selection is not only
for a specific genotype of ESAG7 but rather for a combination
of ESAGs. Supporting this model, a recent article describes a
large family of transmembrane receptor-like adenylate
cyclases, highly represented by the polymorphic ESAG/
GRESAG4, as a parasite tool to control the immune response
of the host [67]. Although, our in vitro approach only mirrors
partially the complex in vivo physiological conditions, our
results support the idea of ESAG genotype selection as
multifunctional tools for adaptation to the host, and VSG-ES
remodelling as the molecular mechanism to achieve the
expression of particular ESAG combinations. Further research
about ESAG variability and function will be crucial to elucidate
the role of these genes in parasite-host crosstalk. In addition,
data on adaptation of other T. b. gambiense strains to
mammalian sera would be useful to extend our observations to
a more general context.
In the field, T. b. gambiense has been found in naturally
infected livestock species such as goats and pigs [12,15]. Our
results support the hypothesis that these animals are able to
harbour T. b. gambiense for long-term periods. Molecular
analyses revealed that pig serum ACLs displayed similar
features to human serum ACLs, strengthening the hypothesis
that swine are the main candidate to act as animal reservoirs of
T. b. gambiense infection. However other animal species,
either domestic or wild, should not be dismissed.
These findings are relevant considering that HAT has been
successfully controlled in several endemic foci and elimination
is in progress in many areas [68]. Hence, a control strategy
only based on detection and treatment of human cases would
not guarantee the elimination of T. b. gambiense in endemic
foci, where animal reservoirs could maintain the infection.
Materials and Methods
Ethics statement
Human blood samples were taken from healthy donors, who
provided written informed consent for the collection of samples.
These samples were specifically obtained for this study. The
procedure was approved by ethical committee of Institute of
Parasitology and Biomedicine Lopez-Neyra (Spanish National
Research Council).
In vitro culture of Trypanosoma brucei gambiense
Bloodstream forms of Trypanosoma brucei gambiense
Eliane strain (MHOM/CI/52/ITMAP 2188) were used in all
experiments [69]. This strain, originally isolated from an
infected patient in Côte d’Ivoire (Ivory Coast) [39], was adapted
to culture in HMI-9 medium [70], first supplemented with 1%
normal human serum (NHS) and 20% foetal calf serum (FCS).
After several months, NHS was no longer required and
parasites effectively proliferated only with 20% FCS. To ensure
the correct identification of our strain within T. b. gambiense
group 1, we checked by PCR the presence of TgsGP [53] and
LiTat 1.3 [71,72]. Cultures were maintained at 37 °C in
humidified atmosphere containing 5% CO2.
For adaptation assays, we maintained parasites in HMI-9
medium adding 20% of different mammalian sera (goat, pig,
human and calf) with a starting density of 5 x 104 parasites/ml.
Goat and pig sera were obtained from Sigma-Aldrich® whereas
FCS was provided by Gibco®. We also tested NHS from
Sigma-Aldrich® but no viable cultures were obtained since
parasites usually collapsed after 7-14 days. This drawback led
us to use human serum from healthy donors. Different batches
of NHS were used in order to avoid potential selection bias: the
batch 1 was a pooled serum from several donors, the batch 2
and 3 came from two different individuals and the batch 4 was
a mix of both 2 and 3 sera. Three independent adaptation
experiments were performed for pig and goat sera. All sera
were inactivated (56 °C for 30 minutes) before used. Cultures
never reached densities over 2 x 106 parasites/ml during the
adaptation before being diluted. After 25 passages (75-105
days) in these media, we labelled the cultures as Adapted Cell
Line (ACL) for the corresponding serum. We did not use clonal
populations in this study since it was assumed that suspected
variability inside population would speed up the selection of
any involved gene.
Disposable Neubauer chambers were used to manually
count parasite density. We estimated duplication time for each
ACL in their corresponding sera. The measure was carried out
starting with 5 x 104 parasites and counting at 48 hours in 24-
well plaques in 1 ml of culture medium.
To confirm the NHS resistance, we cloned by limiting dilution
ACLs coming from pig, calf and goat sera. All clones tested (27
from calf, 17 from pig and 46 from goat sera) were fully
resistant to 10% NHS, while sensitive T. b. brucei controls were
systematically lysed within 16 hours, verifying the constitutive
nature of the NHS resistance in T. b. gambiense [39]. This
assay was conducted in 1 ml culture medium in 24-well plates
with a starting density of 1 x 105 parasites/ml. A cell line
sensitive to NHS (T. b. brucei 1.2, clone 221a derived from
Lister 427) was used as control to ensure the trypanolytic
activity of the serum.
Antibodies anti-VSG production
The VSG expressed in the original line (LiTat 2.1) was
purified by direct isolation from 4 x 108 parasites following the
protocol described elsewhere [73]. We obtained monoclonal
antibodies (mAb) by inoculation of 50 ug of the isolated protein
into BALB-C mice using standard immunization procedures
(see for example 25). Six hybridomas were initially selected by
standard monoclonal selection. The clone 2H5G3, which
showed to be the most suitable for immunofluorescence (IF)
and Western Blot (WB) analyses, was used for all assays.
The VSG expressed in the first human serum ACL (named
LiTat 3.1) obtained in our lab (HS1) was amplified from cDNA
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with primers annealing in splice leader sequence and in 3’
conserved region from all T. brucei VSGs [74]. RT-PCR
product was cloned in pGEM®-T (Promega©) and sequenced.
N-terminal domain was expressed as a fusion protein with
histidine in Single Step (KRX) E. coli Competent Cells
(Promega©) with a pET-28a vector (Novagen®) and induced
with 0.1 mM IPTG and 0.1% rhamnose for 3 hours at 37°C.
Soluble recombinant protein was purified with Ni SepharoseTM
6 Fast Flow (GE Healthcare©) and inoculated into rabbits
following standard immunization protocols. For both VSGs,
peptide mass fingerprint was carried out to check their
correspondence with nucleotide sequences. These sequences
are available in GenBank database with KC257432 (LiTat 2.1)
and KC257433 (LiTat 3.1) accession numbers. After several
attempts we were unable to amplify VSGs corresponding to
PS1, PS3 and GS3. As the primers used to amplify these
genes were designed based on the T. b. brucei genome, slight
sequence differences could hinder the sequencing of some T.
b. gambiense VSGs.
Immunofluorescence
Cells were harvested by centrifugation at 1400 g for 10
minutes at room temperature, washed, and resuspended in
TDB-glucose (KCl 5 mM, NaCl 80 mM, MgSO4 1 mM, Na2HPO4
20 mM, NaH2PO4 2mM, glucose 20 mM, pH 7,4). 2 x 105 cells
were dried on slide, fixed in 1% paraformaldehyde (PFA) for 1
hour, washed with PBS, blocked with 0.5% blocking reagent
(Roche©) and then incubated with mAb anti-LiTat 2.1 (1:10)
and/or rabbit antiserum anti-LiTat 3.1 (1:5000) diluted in 0.5%
blocking reagent. Alexa-Fluor® 488 (anti-mouse) and Alexa-
Fluor® 594 (anti-rabbit) were used as secondary antibodies
(InvitrogenTM). Cells were DAPI stained and visualized with a
fluorescence microscope Zeiss, type Axio Imager A1, equipped
with the AxioVision system. Images were mounted using
ImageJ version 1.44 and Photoshop CS5 (Adobe Systems©)
extended (version 12.1 x64).
Genotyping
Total RNA was extracted from 5 x 107 bloodstream form
trypanosomes using High Pure RNA Isolation Kit (Roche©)
according to the manufacturer’s recommendations. The
amount of total RNA was quantified by spectrophotometric
assay with NanoDrop® system. cDNA was obtained from
retrotranscription (RT) of 1 μg RNA using 300 nmol random
primers in a 25 μl total volume with 100 units of SuperScriptTM
III First-Strand Synthesis System (InvitrogenTM) and was
conducted for 1 hour at 50°C. Partial open reading frames
(ORF) from ESAG3 and ESAG6/7 genes were amplified from
cDNA of each ACL (5U7:5 ’-
TGTGCTGTTGGCTCTTTTGGGA-3’ and Tbg6/7L: 5’-
CAGCACTCCCAACAATAAAACTGAAC-3’ for ESAG6 and
ESAG7 including putative Tf binding sites and E3U: 5’-
TCATGCAACACAAGGATGGT-3’ and E3L: 5’-
TCCCCATATCCTTCGAATTA-3’ for ESAG3).
Due to the lack of T. b. gambiense telomeres in databases,
primers were designed from the published sequences of T.
brucei TREU927. PCR was performed with 1 μl of cDNA, 1X
buffer (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, pH 8.3),
100 μM of each dNTP, 0.5 μM of each primer, 1 U of Fast Start
Taq DNA polymerase (Roche©) and double distilled water
(DDW) until reaching 50 μl final volume. Samples were initially
heated at 93 °C for 2 min and then submitted to 30
amplification cycles (93 °C for 30 seconds, 60 °C for 45
seconds and 72 °C for 90 seconds) followed by a final
extension step at 72 °C for 5 minutes in a Bio-rad© T100TM
Thermal Cycler. Genomic DNA of T. b. gambiense was
amplified as positive control. RT negative controls were
systematically integrated. RT-PCR products were cloned in
pGEM®-T vector (Promega©) and sequenced. Sequences were
manually visualized in order to check their integrity and
ambiguous samples were removed from the analysis.
Alignment was performed with Bioedit Sequence Alignment
Editor 7.0.9.0. Sequences are available in GenBank with the
following accession numbers: ESAG7 genotypes [KC257410-
KC257414], ESAG6 genotypes: [KC257415-KC257418],
ESAG3 genotypes [KC257419-KC2574131]. Clustering trees
were elaborated with sequenced samples using Neighbour-
Joining method with MEGA4 software (Bootstrap=1000).
Distances were computed using the Maximum Composite
Likelihood method and they are in the units of the number of
base substitutions per site.
Transferrin uptake
2 x 106 trypanosomes were harvested and washed with TDB-
glucose plus 1% BSA, resuspended in 250 µl in the same
buffer and incubated for 10 minutes at 37 °C. Then, 5 µg of
human holo-Tf Alexa Fluor® 488-conjugated (InvitrogenTM) were
added. Incubations were carried out for 0 (no Tf), 1, 2.5, 5 and
10 minutes at 37 °C. Cells were then fixed at least for one hour
at 4 °C in 1% PFA diluted in cold PBS. Parasites were finally
washed twice with PBS and labelled cells were analysed with a
Becton Dickinson FACSCaliburTM flow cytometer (BD
Biosciences©) using BD CellQuest™ Pro version 4.0.2
software.
Dextran uptake
Fluid-phase endocytosis was determined using Alexa Fluor®
488-labelled dextran 10,000 (Molecular Probes) as reported
elsewhere [75]. 3 x 106 parasites were resuspended in 10 μl of
TDB-glucose plus 1% BSA and incubated at 37°C for 10 min.
Alexa Fluor® 488-labelled dextran 10,000 was added at 2.5
mg/ml and cells were incubated 10 min at 37 °C. Then
parasites were fixed at least for one hour at 4 °C in 1% PFA
diluted in cold PBS. After washing twice with PBS,
fluorescence was measured in flow cytometer.
RT-qPCR
Quantitative PCR assays were performed in iCycler IQTM
real-time PCR detection system (Bio-Rad Laboratories©); 20 µl
reactions were set up containing 1 µl of cDNA (see Genotyping
section), 0.5 μM of specific forward and reverse primers, 8 µl of
DDW and 10 µl of PerfeCtaTM SYBR® Green SuperMix for iQ
(Quanta Biosciences©). Primers were designed in conserved
regions of the ESAG6/7 gene according to sequences obtained
during genotyping analysis (qTbg6/7U: 5’-
ATTTCCTTCGGTAGCTTGGG-3’ as common primer, qTbg6L:
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5’-TTCACCACCCTCAACGTACA for ESAG6 and qTbg7L: 5’-
CACCGTATTCTCCCCCTTTT-3’ for ESAG7). For TbHpHbR
(Tbg972.6.120) quantification, we designed the following
primers: qTbHpHbRU (5’- AGCAGCTGCAGAGAAATGCT -3’)
and qTbHpHbRL (5’- CTCTCACTGCTCCCACTGAA -3’).
The gene expression level was measured using the
comparative cycle threshold CT method according to Pfaffl,
2001 [76]. The relative expression of different ACLs was
normalized with ATM (PI3 Kinase-like -Tbb927.2.2260-) as
housekeeping gene. Another housekeeping gene, Myosin, was
included as control. All data were analyzed using Bio-Rad CFX
ManagerTM software (version 1.6).
Statistical analysis
We used Student´s t-test to assess significant differences in
the growth of lines before and after adaptation and one-way
ANOVA to compare the Tf uptake. Likelihood Ratio Test,
completed with residues analysis, was used to detect
significant serum-genotype associations. Confidence intervals
(CI) were set at 99% in serum-genotypes associations and
95% in growth and Tf uptake experiments. IBM® SPSStatistics®
software (version 20) was used to perform all statistical
analysis.
Supporting Information
Figure S1.  ESAG6/7 and ESAG3 clustering trees.
Clustering tree of ESAG6/7 (A) and ESAG3 (B) genotypes
found. The trees were constructed using the Neighbor-Joining
method with partial ORF (673-676 bp of ESAG6/7 and 853 bp
of ESAG3). The percentage of replicate trees in which the
associated taxa clustered together in the bootstrap test (1000
replicates) is shown next to the branches. Distances were
computed using the Maximum Composite Likelihood method
and are in the units of the number of base substitutions per
site. T. b. brucei ESAGs 6, 7 and 3 are shown in red.
(TIF)
Figure S2.  Possible recombination scenarios in ACLs.
Schematic representation of different recombination events that
might occur during adaptation process to mammalian sera
tested. (A) Putative active VSG-ES of original cell line adapted
to FCS, containing LiTat 2.1 VSG and probably without ESAG3
functional copies. In some ACLs as GS2, HS4 or GS3,
recombination events could occur downstream the ESAGs 6
and 7 to another VSG-ES containing LiTat 3.1 VSG (B) or
another unidentified VSG (C). Insertion of ESAG3 (and
probably of other nearby ESAGs) could happen from inactive
VSG-ESs or non-telomeric sites by gene conversion (D). This
would explain the presence of the selected ESAG3 genotype
found in HS3 in spite of the identical sequences and the same
VSG found in this line respective to the original one.
Alternatively, in situ switch might occur to a different VSG-ES,
followed by a recombination downstream or upstream ESAG3
to a VSG-ES containing another VSG (E). This would entail a
two steps scenario. However this possibility offers a suitable
explanation for HS1, HS2 and all pig serum ACLs. Black
arrows indicate the promoter sequence, the striped boxes are
the 70-base-pair repeats upstream the VSG gene and white
triangles represent telomeric repeats. Coloured boxes denote
ESAG and VSG genes. The thick black line mirrors the
transcribed genes. FCS: foetal calf serum, GS1/2/3: goat
serum (adaptation experiments 1, 2 or 3), HS1/2/3/4: human
serum (adaptation experiments 1, 2, 3 or 4), PS1/2/3: pig
serum (adaptation experiments 1, 2 or 3). ACL: adapted cell
line.
(TIF)
Table S1.  Summary of ESAG6/7, ESAG3 and VSG
expressed by all ACLs. Numbers represent the main
genotype found in each ACL (see Tables 1 and 2 for further
information). Frequency of the main genotype is given in
parenthesis. If no number is shown, only the specified
genotype was observed. Mixed: population contains more than
3 genotypes with no dominants. FCS: foetal calf serum,
GS1/2/3: goat serum (adaptation experiments 1, 2 or 3),
HS1/2/3/4: human serum (adaptation experiments 1, 2, 3 or 4),
PS1/2/3: pig serum (adaptation experiments 1, 2 or 3). ACL:
adapted cell line.
(DOC)
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